1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Stage IV Lung Cancer AJCC v6: new trials by email Literature Review of Stage IV Lung Cancer AJCC v6 trials Research Report on Stage IV Lung Cancer AJCC v6
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Melanoma (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1) · Urinary Bladder Neoplasms (1)
Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Lung Diseases (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1) · Neuroendocrine Tumors (1) · Nevi and Melanomas (1) · Respiratory Tract Diseases (1)
CTLA-4 Antigen (1) · Disulfides (1) · Immunoglobulin G (1) · Ipilimumab (1) · Nivolumab (1) · tocilizumab (1)
M.D. Anderson Cancer Center (1)
United States (1)